Марказий Осиё эндокринологик журнали 4-том 3-нөмір (2024)
WHAT IS KNOWN ABOUT THE TYPE 1 SODIUM-GLUCOSE CO-TRANSPORTER?
Рахимова Гульнара Нишановна, Иброхимов Худойберди Хусанжон угли
Аңдатпа
From numerous studies, it is known about the role of SGLT-2 inhibitors in reducing glycemia, cardio- and nephroprotection in patients with type 2 diabetes. SGLT-type 1 has been studied somewhat less, the management and activity of which may also be the key to compensating for type 2 diabetes, chronic diseases of the heart, kidneys and other organs and tissues. At the moment, inhibition of SGLT-1 in humans can only be achieved by using combined inhibitors of SGLT-1 /SGLT-2. Drugs with selective inhibition of SGLT-1 are actively studied in animals and in vitro studies. This review is devoted to the principles of the action of sodium-glucose cotransporter type 1, the effect of inhibition of SGLT-1 on pathological conditions, and also evaluated the prospects for the use of iSGLT-1 in humans.
: ингибиторы натрий-глюкозного транспортера 1 типа, ингибиторы натрий глюкозного ко-транспортера 2 типа, сахарный диабет 2 типа, канаглифлозин, сотаглифлозин, мизаглифлозинtype 1 sodium-glucose transporter inhibitors, type 2 sodium glucose transporter inhibitors, type 2 diabetes mellitus, canagliflozin, sotagliflozin, misagliflozinнатрий-глюкоза ко-транспортери 1 тип ингибиторлари, натрий-глюкоза ко-транспортери 2 тип ингибиторлари, қандли диабет 2 тип, канаглифлозин, сотаглифлозин, мизаглифлозин
Метадеректер дереккөзі: журналдың OAI-PMH архиві · Sindex толық мәтінді сақтамайды, дереккөзге сілтеме береді.